Current Report Filing (8-k)
May 02 2022 - 4:54PM
Edgar (US Regulatory)
0001419051
false
0001419051
2022-05-02
2022-05-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): May 2, 2022
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC. |
(Exact
Name of Registrant as Specified in its Charter) |
Nevada |
|
000-54554 |
|
45-1226465 |
(State
or other jurisdiction of
incorporation
or organization) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
701
Wild Rose Lane |
Elk
City, Idaho 83525 |
(Address
of Principal Executive Offices and Zip Code) |
|
(760)
295-7208 |
(Issuer’s
telephone number) |
|
|
(Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock |
|
TSOI |
|
OTC
Markets |
Item
1.01 Entry into a Material Definitive Agreement.
On
April 28, 2022, BIORASI, LLC, and Therapeutic Solutions International Inc, entered into a Master Services Agreement for BIORASI, LLC
as the contract research organization (CRO) to now launch the Company’s Pivotal FDA Registration Clinical Trial assessing efficacy
of its JadiCell™ Adult Stem Cell Product in patients with advanced COVID-19.
Item
9.01 Financial Statements and Exhibits.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
May 2, 2022
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC. |
|
|
|
|
By: |
/s/
Timothy Dixon |
|
|
Timothy
Dixon |
|
|
Chief
Executive Officer |
|
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2023 to Apr 2024